Assoc. Prof. Dr. Jian Yang | Neuroscience | Best Researcher Award
Jian Yang, Ph.D., is an Associate Professor at the School of Medicine, Shanghai University. He holds a B.S. in Chemical Technology and Engineering from Jiangsu Ocean University, an M.S. in Applied Chemistry from Sichuan University, and a Ph.D. in Medicinal Chemistry from China Pharmaceutical University, with joint research training at Massachusetts General Hospital and Harvard Medical School. His research focuses on molecular imaging probe design for early diagnosis of neurodegenerative diseases, PET tracer synthesis, and drug discovery. Dr. Yang has received funding from the China Postdoctoral Science Foundation, the National Natural Science Foundation of China, and the Natural Science Foundation of Shanghai. He actively serves as an editor and reviewer for several international journals.
Education
-
Jian Yang received his Bachelor of Science degree in Chemical Technology and Engineering from Jiangsu Ocean University, Jiangsu, China, in 2003. He pursued his Master of Science in Applied Chemistry at Sichuan University, graduating in 2006. He then completed his Ph.D. in Medicinal Chemistry at China Pharmaceutical University in 2017. During his doctoral studies, he also conducted joint research in Molecular Imaging at Massachusetts General Hospital and Harvard Medical School from 2015 to 2017.
Experience
-
Currently, Jian Yang serves as an Associate Professor at the School of Medicine, Shanghai University, a position he has held since September 2020. Prior to this, he worked as a Postdoctoral Fellow at China Pharmaceutical University from 2017 to 2020. Earlier in his career, he held industrial roles, including Manager at Nanjing JoyMed Pharmaceutical Co., Ltd. from 2010 to 2013, Group Leader at Nanjing Acesys Pharmaceutical Co., Ltd. from 2007 to 2010, and Scientist I at WuXi Apptec in Shanghai from 2006 to 2007.
Awards
-
Jian Yang has been recognized with several research grants and funding awards. These include support from the 62nd China Postdoctoral Science Foundation (No. 1600010008), the National Natural Science Foundation of China (No. 81971677), and the Natural Science Foundation of Shanghai (No. 22ZR1424400).
Skills and Certifications
-
He has extensive skills in molecular imaging, PET tracer synthesis, drug discovery, and new imaging technology development. Jian Yang is actively involved in editorial work, serving as a Guest Associate Editor for Frontiers in Bioengineering and Biotechnology and Frontiers in Immunology, Review Editor for Frontiers in Chemistry, and Contributing Editor for Brain-X. He also reviews for several leading journals including Analytical Chemistry, Theranostics, ACS Applied Materials & Interfaces, and Chemical Engineering Journal.
Research Focus
-
Jian Yang’s research mainly focuses on the design of molecular imaging probes for the early diagnosis of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). He is dedicated to advancing new imaging technologies, synthesizing novel PET tracers for preclinical AD studies, and contributing to drug synthesis and drug discovery research.
Conclusion
-
Dr. Jian Yang is highly suitable for the Research for Best Researcher Award. His multi-disciplinary excellence, global collaboration, translational research outcomes, and sustained publication and funding record make him a standout candidate. His contributions not only advance the scientific understanding of brain diseases but also inspire innovation in molecular diagnostics and therapeutics.
Publications
- Novel Dual-Functional Half-Curcumin Analogues as a Fluorescent and PET Probe for β-Amyloid Imaging in the Alzheimer’s Disease APP/PS1 Model
Authors: Haijun Yang, Ke Li, Tingfang Wang, Jianguo Lin, Jian Yang
Journal: ACS Chemical Neuroscience, 2025 - Dual Targeting of Neuropilin-1 and Glucose Transporter for Efficient Fluorescence Imaging of Cancer
Authors: Jianwei Zhu, Can Zhou, Jian Yang, Zhenhua Wang
Journal: Molecular Imaging and Biology, 2025 - Targeted Radionuclide Therapy of CLDN18.2-Positive Gastric Cancer with [131I]I-Zolbetuximab: An In Vitro and In Vivo Study
Authors: Yang Wang, Shuhua He, Lin Ma, Zheng Li, Qingnuan Li
Journal: Molecular Pharmaceutics, 2025